Argenx stock advances as H.C. Wainwright reiterates Buy rating

H.C. Wainwright reiterated its Buy rating and $720 price target for Argenx SE (ARGX), driven by the advancement of ARGX-119 to late-stage clinical development after positive Phase 1b data, marking its third such pipeline asset. This comes as analysts maintain a strong bullish consensus, with targets reaching $1,113, and the company reports impressive 82% revenue growth over the last twelve months. Despite an FDA safety signal for Vyvgart Hytrulo, other firms like Citi, JMP Securities, and TD Cowen largely maintain positive ratings, underscoring confidence in Argenx's strong financial performance and the broad potential of its Vyvgart franchise and pipeline.

Analysis

Argenx SE (ARGX) is experiencing strong positive sentiment from the analyst community, underscored by H.C. Wainwright's reiteration of its Buy rating and a $720 price target. This confidence is primarily fueled by the advancement of its third pipeline asset, ARGX-119, into late-stage clinical development following a successful Phase 1b proof-of-concept study that met its primary safety and tolerability endpoints. This pipeline progression is supported by robust financial performance, including an 82% revenue growth over the last twelve months and a market capitalization of $33.7 billion. Despite this positive momentum, a key risk has emerged with the U.S. FDA evaluating a potential safety signal for the company's established product, Vyvgart Hytrulo, in CIDP patients. However, major analysts like Citi and JMP Securities appear to be largely discounting this risk for now, maintaining Buy/Outperform ratings and citing the strength of the core VYVGART franchise and its expansion potential into new indications such as myositis and Sjogren’s disease, which TD Cowen highlights as a source of significant upside. The broad analyst consensus remains bullish, with price targets ranging from $586 to $1,113, suggesting the market perceives the company's growth drivers and pipeline depth as outweighing the current regulatory overhang.

Key Decisions for Investors

• Given the strong analyst consensus and 82% revenue growth, investors may consider the current price an opportunity, as the pipeline advancement of ARGX-119 provides an additional long-term growth catalyst.
• It is critical to closely monitor communications from the FDA regarding the Vyvgart Hytrulo safety signal, as any definitive negative ruling could materially impact the stock's valuation and sentiment.
• Investors should watch for upcoming catalysts, specifically the detailed data presentation for ARGX-119 and further trial results for VYVGART in new indications, as these could reinforce the bull case and drive the stock toward higher analyst price targets.
• For those with existing positions, the consistent reiteration of positive ratings from multiple firms, despite the FDA news, suggests the market currently views the pipeline's potential as a compelling reason to hold through the volatility.